摘要
目的探讨头孢哌酮钠舒巴坦钠对缺血性脑血管病患者凝血功能的影响。方法选取医院神经内科收治的缺血性脑血管病合并肺炎患者60例,根据抗感染治疗方案不同分为对照组(采用哌拉西林钠他唑巴坦钠治疗)和观察组(采用头孢哌酮钠舒巴坦钠治疗),各30例,观察两组患者治疗前后的凝血功能[凝血酶时间(TT)、凝血酶原时间(PT)、部分活化凝血酶时间(APTT)]及血小板计数(PLT)的变化。结果与治疗前比较,两组患者治疗后的PT和APTT均明显升高(P<0.01),且观察组均显著高于对照组(P<0.05);两组患者治疗前后的TT和PLT组内、组间比较,差异均无统计学意义(P>0.05)。结论头孢哌酮钠舒巴坦钠治疗缺血性脑血管病合并肺炎,可延长PT和APTT,对凝血功能有显著影响,临床使用时需警惕出血风险。
Objective To investigate the effect of cefoperazone sodium and sulbactam sodium on the coagulation function in patients with ischemic cerebrovascular disease.Methods A total of 60 patients with ischemic cerebrovascular disease complicated with pneumonia were selected and divided into the control group(treated with piperacillin sodium tazobactam sodium)and experimental group(treated with cefoperazone sodium and sulbactam sodium)based on different anti-infective regimens,30 cases in each group.The changes in the coagulation functions included platelet count(PLT),activated partial thromboplastin time(APTT),prothrombin time(PT)and thrombin time(TT)were observed.Results Compared with before treatment,the PT and APTT increased significantly(P<0.01)after treatment,and the experimental groups increased significantly more than the control group(P<0.05).There was no significant difference in TT and PLT between the groups at before and after treatment(P>0.05).Conclusion Cefoperazone sodium and sulbactam sodium in the treatment of ischemic cerebrovascular disease with pneumonia can prolong PT and APTT,have a significant effect on coagulation function,so we should be vigilant against bleeding risks during clinical use.
作者
梁河
蒙光义
钟丽球
周丽娟
韦凤华
庞家容
LIANG He;MENG Guangyi;ZHONG Liqiu;ZHOU Lijuan;WEI Fenghua;PANG Jiarong(Yulin First People's Hospital,Yulin,Guangxi,China 537000)
出处
《中国药业》
CAS
2020年第9期148-150,共3页
China Pharmaceuticals
基金
广西玉林市科学研究与技术开发计划项目[玉市科20171606]。
关键词
头孢哌酮钠舒巴坦钠
缺血性脑血管病
凝血功能
cefoperazone sodium and sulbactam sodium
ischemic cerebrovascular disease
coagulation function
